Articles

Getting control of bleeding

Spark and Pfizer announce updated data for ongoing hemophilia B study
Written byJennifer Clifford
| 3 min read

PHILADELPHIA—In December, Spark Therapeutics and Pfizer Inc. announced updated preliminary data from the first nine infused participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for hemophilia B.

Hemophilia B is a rare, genetic bleeding disorder, most commonly affecting males, that causes the blood to take longer to clot than normal. This can cause excessive and recurrent bleeding, often into the muscles and joints, and carries the potential to be life-threatening. Patients with hemophilia B have a deficiency of a protein in the blood, clotting factor IX, which is currently treated with intravenous infusions of either plasma-derived or recombinant factor IX to control and prevent bleeding episodes.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.